Free Trial
NASDAQ:RYTM

Rhythm Pharmaceuticals Q2 2025 Earnings Report

Rhythm Pharmaceuticals logo
$88.30 +3.07 (+3.60%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$86.20 -2.10 (-2.38%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.64
Beat/Miss
N/A
One Year Ago EPS
N/A

Rhythm Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$43.72 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rhythm Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Rhythm Pharmaceuticals Earnings Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Rhythm Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rhythm Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rhythm Pharmaceuticals and other key companies, straight to your email.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

View Rhythm Pharmaceuticals Profile

More Earnings Resources from MarketBeat